On behalf of the entire team, I would like to thank our historical shareholders who took part in this transaction and to the new shareholders who enabled it to be a success. Thanks to these funds, it is with determination that we will be able to accelerate our clinical developments in the treatment of cardiovascular emergencies, which remain a crucial public health challenge. We are proud to be one of the few listed companies in the world which specializes in developing a new drug for ischemic strokes. This focus makes ACTICOR a unique value in the stock market for our shareholders, and we will do everything we can to successfully meet the next stages of our developments.
– Gilles AVENARD, Chief Executive Officer of Acticor Biotech